RTX-240 Monotherapy and in Combination With Pembrolizumab
a study on Acute Myeloid Leukemia Solid Tumor
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD
- Dates
- study startedestimated completion
Description
Summary
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).
Official Title
Phase 1/2 Study of RTX-240 Monotherapy and in Combination With Pembrolizumab
Details
This is a Phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion study to determine the safety and tolerability, recommended phase 2 dose and optimal dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients with relapsed/refractory (R/R) or locally advanced solid tumors (Phase 1/2) or R/R acute myeloid leukemia (Phase 1 only), and RTX-240 in combination with pembrolizumab in adult patients with R/R or locally advanced solid tumors (Phase 1 only). RTX-240 is a cellular therapy that co-expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha, with the goal of stimulating the innate and adaptive immune systems for the treatment of cancer. The study includes a monotherapy dose escalation phase (Phase 1) followed by an expansion phase (Phase 2) in specified tumor types.
Keywords
Solid Tumor, AML Adult Pembrolizumab RTX-240
Eligibility
You can join if…
Open to people ages 18 years and up
- Signed written informed consent obtained prior to study procedures
- Patients ≥18 years with an ECOG 0 or 1 (Parts 1, 2 and 4) or 0-2 (Part 3).
- Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no standard therapy exists (Parts 1, 2 and 4), or for which the patient is ineligible or has declined standard therapy or R/R, cytologically confirmed AML (Part 3).
- Disease must be measurable per Response Evaluation Criteria
- The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment.
- Adequate Organ Function and Blood Cell Counts (Parts 1, 2, and 4) as defined by the protocol:
- GFR ≥ 50 mL/min/1.73,
- AST and ALT ≤ 3 × the ULN and total bilirubin ≤ 1.5 × ULN, in the absence of cancer within the liver
- Or AST and ALT ≤ 5 × ULN and total bilirubin ≤ 3 × ULN, in the setting of primary or metastatic liver tumors.
ANC ≥ 1 × 103/μL without myeloid growth factor support for at least one week prior to enrollment
Platelet count ≥ 75 × 103/μL
- Hemoglobin should be ≥ 9 g/dL without red blood cell transfusion for at least one week
- Patients must have LVEF ≥ 45%
- Patients enrolling into Part 2 of the study must be diagnosed with NSCLC, RCC, or anal cancers
- Patients enrolling into Part 4 must be diagnosed with NSCLC or RCC
- Patients enrolling into either Part 2 or 4 must have 2 or fewer prior treatment regimens. If patient received a prior PD-1/PD-L1-containing regimen, a prior response is required.
You CAN'T join if...
- Primary central nervous system (CNS) malignancy or CNS involvement, unless asymptomatic, previously treated, and stable without steroids (Parts 1, 2 and 4) or known CNS leukemia (Part 3).
- Known hypersensitivity to any component of study treatment or excipients.
- Positive antibody screen using institution's standard type and screen test.
- Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
- Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic anemia
- Class III or IV cardiomyopathy per the New York Heart Association criteria
Leukemic blast count ≥ 25 x 103/µL (Part 3)
- Concomitant conditions requiring active immunosuppression
- History of clinically significant Grade 3 or higher immune related Adverse Event (irAE)
- Prior malignancy within the past 3 years, with protocol specified exceptions
- History of severe hypersensitivity to a PD-1/PD-L1 blocking Ab unless previously rechallenged successfully (Part 4)
- Current noninfectious pneumonitis or a history of radiation pneumonitis or pneumonitis that required steroids, or Grade 2 or greater immune related pneumonitis, hepatitis, hypophysitis, or other endocrinopathy (Part 4)
Locations
- University of California San Diego
accepting new patients
La Jolla California 92093 United States - The Angeles Clinic & Research Institute
accepting new patients
Los Angeles California 90025 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rubius Therapeutics
- ID
- NCT04372706
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 166 study participants
- Last Updated